RTW Biotech Opportunities Ltd (RTW) ORD NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
$1.42
$1.44
$1.73
197.00
$1.43
$1.40
$1.26
-29.19%
$0.04 (2.51%) Previous:
$0.04
50,916
n/a
USD
Price
-
Net Asset Value (NAV)
Performance
1 week 1W | 0.7% | 1 year 1Y | 3.97% |
---|---|---|---|
1 month 1M | 4.64% | 2 years 2Y | 19.01% |
3 months 3M | 5.57% | 3 years 3Y | 19.1% |
6 months 6M | 5.88% | 5 years 5Y | 4.35% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | Russell 2000 Biotech Growth |
---|---|
Annual management charge: | n/a |
Performance fee: | Yes |
Ongoing charge: | 1.87% |
Dividend yield: | n/a |
Dividend frequency: | None |
Total assets: | £661m |
Gross gearing: | 0% |
Market capitalisation:Market cap.: | £480m |
Shares in issue: | 335.71 million |
Legal structure | Closed Ended Investment Company |
Domicile: | Guernsey |
ISIN | GG00BKTRRM22 |
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please see our Sustainability Labels page for more information.
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | $197.00 |
---|---|
Latest actual NAV: | n/a |
Latest actual NAV date: | n/a |
Premium/Discount: | -29.19% |
12m average Premium/Discount: | -24.95% |
NAV frequency: | Monthly |
Security | Weight |
---|---|
Healthcare.com Inc Shs Stock Settlement | 26.89% |
Avidity Biosciences, Inc. | 13.18% |
Rocket Pharmaceuticals Inc | 7.55% |
Madrigal Pharmaceuticals Inc | 7.26% |
Dyne Therapeutics Inc Ordinary Shares | 5.73% |
Avidity Biosciences Inc Ordinary Shares | 5.40% |
Artios Pharma Limited | 5.25% |
Ji Xing Pharmaceuticals Ltd. | 5.02% |
Avidity Biosciences, Inc. | 0.75% |
Rocket Pharmaceuticals, Inc. | 0.50% |
Sector | Weight |
---|---|
Healthcare | 52.84% |
Country | Weight |
---|---|
United States | 52.84% |
Key Dates
Launch date: | 29 October 2019 |
---|---|
Financial year end: | December |
Next AGM: | May 2025 |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.